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Background: Highly active antiretroviral therapy (HAART) has extended life expectancy and enhanced the well-being
of HIV-positive individuals. Since there are concerns regarding HAART-mediated onset of cardio-metabolic diseases in
the long-term, we evaluated the anthropometric profile of black HIV-infected individuals in a peri-urban setting
(Western Cape, South Africa).
Methods: A cross sectional study design was followed to describe the gender differences in different HAART
treatment groups. HIV-positive patients (n = 44 males, n = 102 females; 20–40 years) were recruited for three
groups: 1) control (HIV-positive, HAART-naïve), 2) HIV-positive (<3 years HAART), and 3) HIV-positive (>3 years HAART).
Results: All participants underwent comprehensive anthropometric and bio-electrical impedance analyses. No
significant differences were observed in the male treatment groups. HAART-naïve females are mostly overweight
(73.90 ± 2.79). This is followed by a period of muscle wasting seen in the triceps skinfold (29.30 ± 2.19 vs 20.63 ± 1.83;
p < 0.01), muscle mass (22.23 ± 0.46 vs 19.82 ± 0.54; p < 0.01), and fat free mass (49.40 ± 1.08 vs 44.16 ± 1.21; p < 0.01)
upon HAART initiation (<3 years HAART). Thereafter all parameters measured had levels similar to that seen for the
female HAART-naïve group. Females on <3 years HAART exhibited significantly decreased body cell mass (p < 0.01),
protein mass (p < 0.01), muscle mass (p < 0.01), fat free mass (p < 0.01), and fat mass (p < 0.001) versus matched
HAART-naïve controls. The W:H ratio for the female treatment groups placed the females overall at a higher risk
for developing cardiovascular disease compared to the males.
Conclusions: This study found striking gender-based anthropometric differences in black South African HIV-positive
individuals on HAART. We also conclude from this observational study that no significant differences were found in the
different male treatment groups. All female body composition parameters initially showed lower values (<3 years
HAART). The female treatment group (>3 years HAART) displayed values similar to that seen in the HAART-naïve
group. Higher W:H ratios in females receiving longer-term HAART potentially increases their risk for the future
onset of cardio-metabolic complications.
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South Africa is currently burdened with the highest
global prevalence of HIV-AIDS, with ~6.4 million HIV-
infected individuals making up ~12.2% of the population
[1]. Although the increased roll-out of highly active anti-
retroviral treatment (HAART) is blunting the spread of
HIV-AIDS and extending life expectancy [2], there are
growing concerns regarding longer-term co-morbidities
such as the onset of type 2 diabetes and cardiovascular
diseases (CVD) [3-6]. In parallel, recent studies demon-
strate that increased obesity, and especially abdominal
fat, is associated with a greater risk for CVD onset
within the wider populace [7,8]. Since the broader
South African population is also faced with an increas-
ing obesity prevalence, the country is strongly chal-
lenged by a so-called dual burden of disease [2]. This
burgeoning health issue will result in serious conse-
quences by impacting on the overall well-being and
health of its population, and also by stunting economic
growth and development.
Previous studies show that HAART can trigger body
composition changes leading to visceral fat accumulation
in HIV-infected persons [9]. Moreover, ~30% of HAART-
treated individuals display some evidence of anthropo-
metric and body composition changes, including weight
gain, fat redistribution and other significant metabolic
alterations [10,11]. Despite such concerns, limited
research has been conducted on sub-Saharan African
populations to evaluate potential cardio-metabolic risk
in HIV-positive persons. Here the emphasis has largely
been placed on evaluating cardio-metabolic co-
morbidities in developed countries [3]. However, a
recent study performed on HIV-positive South African
urban women found that HAART was associated with
increased central fat gain and decreased levels of per-
ipheral fat [12]. In agreement, others reported that
HIV-positive individuals exhibited subcutaneous fat
displacement accompanied by muscle wasting [13].
In light of this paucity of data within the South
African HIV-infected population, the current study
assessed anthropometric changes within a peri-urban
setting (Paarl, Western Cape, South Africa). We also
set out to provide novel insights into the question of
gender-based anthropometric changes in response to
HIV-positive persons on HAART since this remains
relatively poorly understood.
Methods
Design and subjects
This cross-sectional study was performed during 2012
and 2013 and evaluated gender-based body composition
differences between HIV-positive HAART and HAART-
naïve individuals. Black South African males and fe-
males (n = 146) were randomly recruited and selectedfrom ~1, 500 out-patients at the TC Newman Commu-
nity Day Care Centre and the Mbekweni Clinic from
the Paarl and Wellington health districts, respectively.
Paarl and Wellington are closely located neighboring
towns within a peri-urban setting, and located ~35
miles from Cape Town (Western Cape, South Africa).
HIV positive males or females that are on treatment,
and/or newly diagnosed HIV patients (for controls); age
ranges between 20 and 40 years; residents of Paarl,
Wellington and the Drakenstein region were included
in the study. No pregnant or lactating females or pa-
tients diagnosed with acute diseases were entered into
the study. Participants were subsequently divided into
two arms i.e. a) HAART-naïve control group (n = 48
[32.9%]; n = 13 males [8.9%] and n = 35 females
[24.0%]), and b) HIV-positive HAART groups (n = 98
[67.1%]; n = 31 males [21.2%] and n = 67 females
[45.9%]), respectively. The HAART group was further
split into two sub-groupings, i.e. HAART for less and
longer than three years, respectively. Such sub-groups
were subsequently analyzed in a gender-dependent
manner. We employed this particular sub-group classi-
fication based on previous research that found that
HAART-induced anthropometric and metabolic alter-
ations manifested in a temporal manner [14].
Ethical considerations
Both the Human Research Ethics Committee of
Stellenbosch University and the Western Cape Gov-
ernment Ethics Committee approved this study (S12/
03/073 and 2012 RP 100). Written consent was obtained
from all participants after volunteering and agreeing to
take part in the study. Participants were also free to with-
draw from the study if they no longer wished to continue
and had access to their standard medical care throughout
the duration of the study.
Testing procedures
All participants were informed of the physical testing
procedures. Conventional anthropometry was per-
formed in duplicate and included base measurements,
circumferences and skin folds. Height was measured to
the nearest 0.1 cm with a portable stadiometer (Seca
United Kingdom, Birmingham, England), while weights
were determined (with minimal clothing) to the nearest
0.01 kg using a calibrated Seca 634 scale (Seca United
Kingdom, Birmingham, England). Waist circumference
(WC) was measured with a Lufkin® executive thin line
tape measure (Lufkin W606PM) (Apex Tool Group,
USA). The circumference was determined at the nar-
rowest point between the lower costal border and the
top of the iliac crest perpendicular to the long axis of
the trunk [15]. The hip circumference (HC) was taken
at the greatest posterior protuberance of the gluteal
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waist-to-hip (W:H) ratio were calculated by employing
the parameters here described. The triceps skinfold
(TSF) was measured using a skinfold caliper (Harpen-
den, Baty International, West Sussex, UK), and the TSF
site was located at the point on the posterior area of
the right arm in the mid-line of the level of the mid-
acromiale radiale landmark.
Bio-electrical impedance analysis (BIA) was completed
by employing a Maltron Bioscan 9200 standard tetra-
polar multi-frequency analyzer (Maltron International,
Rayleigh, Essex, UK) that analyzes the percentage fat, fat
mass, body cell and muscle mass. Here a BIA pre-test
protocol was implemented, i.e. a) emptying of the blad-
der, and b) removal of all metal objects from the skin. In
addition, participants were instructed to lie on the exam-
ination bed with their legs and arms slightly apart with
no limbs touching the body, while conduction electrodes
were placed on both the right hand and right foot.
Statistical analyses
Statistical analyses were performed using Statistica
version 12 software (Statsoft, Tulsa OK, USA). The
means, standard deviations and standard error of the
mean (SEM) were calculated for all parameters, and
factorial analysis of variance (ANOVA) employed to
evaluate differences between various groupings and
sub-groupings here investigated. The Bonferroni post-
hoc test was subsequently used to assess the signifi-
cance of differences found between groups. We also
completed additional analyses with the W:H data (as
marker of fat distribution), i.e. Spearman correlation
co-efficient was performed on W:H and CD4 cell
counts. P-values of ≤ 0.05 were considered statistically
significant and the mean ± SEM was used for all
results reported.Table 1 Summary of anthropometric characteristics for all pa
Variable Male
(n = 44)
Age (years) 33.30 ± 0.69
Height (cm) 170.80 ± 0.84
Weight (kg) 62.70 ± 1.60
BMI (kg/m2) 21.50 ± 0.54
Triceps skinfold (mm) 9.60 ± 1.10
Mid-upper arm circumference (cm) 26.70 ± 0.55
Waist circumference (cm) 76.80 ± 1.60
Hip circumference (cm) 89.30 ± 1.20
Waist-to-height ratio 0.45 ± 0.01
Waist-to-hip ratio 0.86 ± 0.01
Values represent mean ± SEM. All male subjects were compared to female subjects
and p<0.05 considered as statistically significant.Results
Participant and body composition characteristics
Of the 146 participants included, most were female
(n = 102; 70%) with a mean patient age of 30.9 ± 0.58
years, compared to 30% males (n = 44) with a mean
patient age of 33.3 ± 0.69 years (refer to Tables 1 and
2 for summary of descriptive characteristics). We ini-
tially assessed the data in a gender-dependent manner
for all of the study participants (HIV-positive HAART
and HAART-naïve). Here our data reveal that female
participants displayed increased levels of adiposity as
determined by anthropometric analysis. These data
were confirmed by the BIA analysis that showed
lower levels of fat free mass in female participants. In
addition, females exhibited attenuated levels of glyco-
gen and total body potassium and calcium (Table 2).
Combined HIV-positive and HIV HAART participant and
body composition characteristics
To gain further insight into body composition changes,
we next compared the HIV-positive HAART versus
HAART-naïve groups but independently of gender. The
HIV-positive HAART group displayed a greater W:H ra-
tio suggesting some degree of metabolic remodeling with
treatment (Table 3). Although both WC and HC were
lower in the HAART group, the percentage decrease was
higher for the HC thereby explaining the higher W:H ra-
tio found. The BIA analysis demonstrates that protein
and mineral content levels were reduced with HAART
(p < 0.05 for all) (see Table 4).
Female specific participant and body composition
characteristics
When the study groups were further sub-divided to take
into account the duration of treatment, we established
that female participants on HAART for less than 3 yearsrticipants, irrespective of group specifics
Female p-value
(n = 102)
30.90 ± 0.58 p < 0.05
157.90 ± 0.63 p < 0.001
70.80 ± 1.80 p < 0.01
28.30 ± 0.70 p < 0.001
27.50 ± 1.30 p < 0.001
30.90 ± 0.60 p < 0.001
90.60 ± 1.50 p < 0.001
105.30 ± 1.40 p < 0.001
0.57 ± 0.01 p < 0.001
0.86 ± 0.01 -
according to their anthropometric characteristics. Student t-tests were used
Table 2 Summary of BIA characteristics for all participants, irrespective of group specifics
Variable Male Female p-value
(n = 44) (n = 102)
CD4 314.69 ± 39.92 388.51 ± 23.49 -
Body cell mass: Fat free mass 0.58 ± 0.002 0.55 ± 0.00 p < 0.001
Resting metabolic rate (kcal) 1776.41 ± 20.64 1553.73 ± 10.55 p < 0.001
Fat free mass (kg) 53.46 ± 0.95 48.29 ± 0.70 p < 0.001
Fat free mass (%) 85.89 ± 0.70 70.30 ± 0.90 p < 0.001
Fat mass (kg) 9.24 ± 0.71 22.52 ± 1.15 p < 0.001
Fat percentage (%) 14.11 ± 0.70 29.70 ± 0.90 p < 0.001
Body cell mass (kg) 30.77 ± 0.45 26.58 ± 0.38 p < 0.001
Extracellular mass (kg) 22.69 ± 0.50 21.72 ± 0.33 -
Protein mass (kg) 9.24 ± 0.33 9.07 ± 0.14 -
Mineral mass (kg) 3.24 ± 0.12 3.71 ± 0.06 p < 0.001
Muscle mass (kg) 27.24 ± 0.48 21.65 ± 0.30 p < 0.001
Total body Potassium (g) 146.89 ± 2.13 117.52 ± 1.68 p < 0.001
Total body Calcium (g) 1185.32 ± 15.42 972.87 ± 12.11 p < 0.001
Glycogen (g) 521.64 ± 7.55 450.36 ± 6.38 p < 0.001
Values represent mean ± SEM. All male subjects were compared to female subjects according to their BIA characteristics. Student t-tests were used and p < 0.05
considered as statistically significant.
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eters (Table 5). In agreement most of the BIA character-
istics were significantly attenuated in the HAART group
(Table 6). For male participants, no significant differ-
ences were found between the HAART-naïve and
HAART groups (data not shown). Together these data
suggest some degree of muscle wasting in females re-
ceiving HAART during the first three years of treatment.
Triceps skinfolds and W:H ratio
To further understand the nature of body composition
changes found in female participants, we next compared
anthropometric and BIA data in a temporal fashionTable 3 Summary of anthropometric characteristics for all pa
treated groups, irrespective of gender
Variable HIV-positive
(n = 48)
Age (years) 30.15 ± 0.86
Height (cm) 162.00 ± 1.10
Weight (kg) 71.68 ± 2.25
BMI (kg/m2) 27.38 ± 0.94
Triceps skinfold (mm) 24.44 ± 2.08
Mid-upper arm circumference (cm) 30.30 ± 0.80
Waist circumference (cm) 87.41 ± 2.13
Hip circumference (cm) 103.84 ± 1.97
Waist-to-height ratio 0.54 ± 0.01
Waist-to-hip ratio 0.84 ± 0.01
Values represent mean ± SEM. HIV-positive and HIV-HAART subjects were compared and(HAART <3 years versus >3 years) for both genders. Here
factorial analysis of variance (ANOVA) indicated a main
effect of gender (p < 0.001), and treatment and gender
(p < 0.05). Overall, females displayed significantly larger
TSFs compared to males irrespective of treatment status
(Figure 1A). Thus, even though the female TSF values de-
creased during the earlier period of HAART, this was still
significantly higher than their male counterparts at the
same stage. Unlike male participants, TSF values with lon-
ger treatment duration for females were similar to that of
the HAART-naïve group. However, this trend was not
present with the W:H ratio data, where no significant differ-
ences were observed between any of the groups (Figure 1B).rticipants in the HIV-positive and HIV-positive HAART
HIV-HAART p-value
(n = 98)
34.38 ± 0.53 p < 0.05
171.62 ± 0.90 -
60.00 ± 1.70 -
20.42 ± 0.70 -
7.03 ± 1.42 -
25.90 ± 0.58 -
76.30 ± 1.60 -
87.10 ± 1.50 p < 0.05
0.45 ± 0.01 -
0.88 ± 0.009 p < 0.05
Student t-tests were used and p < 0.05 considered as statistically significant.
Table 4 Summary of BIA characteristics for all participants in the HIV-positive and HIV-positive HAART treated groups,
irrespective of gender
Variable HIV-positive HIV-HAART p-value
(n = 48) (n = 98)
CD4 323.00 ± 34.10 426.30 ± 25.20 -
Body cell mass: Fat free mass 0.56 ± 0.002 0.58 ± 0.002 -
Resting metabolic rate (kcal) 1647.00 ± 23.00 1742.80 ± 15.30 -
Fat free mass (kg) 51.20 ± 1.04 51.89 ± 0.73 -
Fat free mass (%) 73.20 ± 1.50 86.88 ± 1.09 -
Fat mass (kg) 20.40 ± 1.67 8.16 ± 1.19 -
Fat percentage (%) 26.80 ± 1.52 13.12 ± 1.09 -
Body cell mass (kg) 28.47 ± 0.58 29.90 ± 0.41 -
Extracellular mass (kg) 22.72 ± 0.48 21.90 ± 0.34 -
Protein mass (kg) 9.60 ± 0.21 8.71 ± 0.18 p < 0.05
Mineral mass (kg) 3.77 ± 0.084 3.05 ± 0.07 p < 0.05
Muscle mass (kg) 23.90 ± 0.58 26.35 ± 0.40 -
Total body Potassium (g) 129.00 ± 3.10 142.90 ± 2.11 -
Total body Calcium (g) 1055.80 ± 22.20 1156.70 ± 15.25 -
Glycogen (g) 482.60 ± 9.85 507.54 ± 6.92 -
Values represent mean ± SEM. HIV-positive and HIV-HAART groups were compared. Student t-tests were employed and p < 0.05 considered as statistically significant.
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(PM), fat mass (FM) and muscle mass (MM)
The BIA analyses showed analogous patterns for the fe-
male participants, i.e. lower BCM early on followed by
recovery with longer HAART (Figure 2A). A main effect
of treatment (p < 0.05), gender (p < 0.001), and treatment
and gender (p < 0.05) was evident when BCM was ana-
lyzed using factorial ANOVA. Bonferroni post-hoc tests
indicated significant differences in the female treatment
groups, however, males displayed a higher BCM overall,
except for the >3 year group. The FFM data demon-
strated a similar arrangement, with effects of treatmentTable 5 Summary of anthropometric characteristics for femal
Variable HIV-positive
(n = 35)
Age (years) 29.40 ± 1.05
Height (cm) 159.06 ± 1.04
Weight (kg) 73.90 ± 2.79
BMI (kg/m2) 29.15 ± 1.10
Triceps skinfold (mm) 29.30 ± 2.19
Mid-upper arm circumference (cm) 31.30 ± 1.00
Waist circumference (cm) 91.30 ± 2.46
Hip circumference (cm) 108.50 ± 2.07
Waist-to-height ratio 0.57 ± 0.02
Waist-to-hip ratio 0.84 ± 0.01
Values represent mean ± SEM. Student t-tests were employed and p < 0.05 were co(p < 0.05), gender (p < 0.001) and treatment and gender
(p < 0.05) (Figure 2B).
Similar findings were established for PM, and a main
effect of treatment (p < 0.05) was evident according to
factorial ANOVA (Figure 2C). In line with our findings
for the other parameters studied here, PM for females in
the <3 year group was attenuated versus controls
(p < 0.05). Females generally displayed a higher FM com-
pared to their male counterparts (Figure 3A) and the
trend was like before. However, the male participants
started with a markedly reduced FM that remained rela-
tively unchanged for the duration of HAART. Factoriales in the HIV-positive and HIV-HAART (<3 years) group
<3 years p-value
(n = 29)
29.66 ± 1.14 -
156.24 ± 1.32 -
59.94 ± 2.87 p < 0.001
24.43 ± 1.08 p < 0.01
20.63 ± 1.83 p < 0.01
27.68 ± 1.08 p < 0.05
83.46 ± 2.60 p < 0.05
97.71 ± 2.49 p < 0.01
0.53 ± 0.02 -
0.85 ± 0.01 -
nsidered as statistically significant.
Table 6 Summary of BIA characteristics for females in the HIV-positive and HIV-HAART (<3 year) group
Variable HIV-positive <3 years p-value
(n = 35) (n = 29)
CD4 348.62 ± 41.89 307.89 ± 32.06 -
Body cell mass: Fat free mass 0.55 ± 0.001 0.55 ± 0.002 -
Resting metabolic rate (kcal) 1579.26 ± 17.00 1498.41 ± 20.05 p < 0.01
Fat free mass (kg) 49.40 ± 1.08 44.16 ± 1.21 p < 0.01
Fat free mass (%) 68.52 ± 1.35 75.86 ± 1.79 p < 0.01
Fat mass (kg) 24.40 ± 1.83 15.83 ± 1.79 p < 0.01
Fat percentage (%) 31.49 ± 1.35 24.15 ± 1.79 p < 0.01
Body cell mass (kg) 27.16 ± 0.58 24.39 ± 0.63 p < 0.01
Extracellular mass (kg) 22.24 ± 0.50 19.78 ± 0.59 p < 0.01
Protein mass (kg) 9.52 ± 0.20 8.24 ± 0.29 p < 0.001
Mineral mass (kg) 3.89 ± 0.008 3.38 ± 0.12 p < 0.001
Muscle mass (kg) 22.23 ± 0.46 19.82 ± 0.54 p < 0.01
Total body Potassium (g) 120.10 ± 2.60 107.77 ± 2.81 p < 0.01
Total body Calcium (g) 991.54 ± 18.77 902.38 ± 20.31 p < 0.01
Glycogen (g) 460.34 ± 9.89 413.24 ± 10.71 p < 0.01
Values represent mean ± SEM. Student t-tests were employed and p < 0.05 were considered as statistically significant.
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and treatment and gender (p < 0.05). Here gender dif-
ferences were evident between the controls and the >3
year HAART treatment groups (p < 0.001 for both). For
MM, analogous patterns were found for female partici-
pants as before, although males generally exhibited a
greater MM compared to females (Figure 3B). A main
effect of treatment (p < 0.05), gender (p < 0.001) and treat-
ment and gender (p < 0.05) was evident.
W:H ratio and CD4 cell count
We also performed correlations for W:H ratio versus
CD4 count (between genders) for the HAART-naïve and
HAART (<3 years, >3 years) groups, respectively. The
HAART-naïve group did not reveal any significant
correlation between W:H ratio and CD4 count for malesFemales Males
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this effect was abolished in the male participants while
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p < 0.05) (Figure 4C).
Discussion
This study found striking gender-based anthropometric
and BIA characteristic differences in black South African
HIV-positive individuals on HAART. The data reveal
that females are mostly overweight by the time HAART
is initiated, followed by a period of muscle wasting,
whereafter (>3 years HAART) weight levels return to
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male treatment groups) displayed elevated W:H ratios
after prolonged HAART, therefore potentially putting
them at increased risk for the future onset of cardio-
metabolic complications.
Our finding that the majority of black HIV-positive
women (at start of HAART) displayed obesity is in
broad agreement with others [16] who reported that
the prevalence of obesity is sharply increasing within
the larger South African population. Here they found a
greater prevalence of obesity in females compared to
males (56% versus 29%) (according to BMI cut-off
values), higher than what is typically observed for other
African countries [12,16]. Since some African cultures0
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explain higher obesity levels in HIV-infected females
here studied. In addition, black women are less pres-
sured to be slim and relate thinness with illness and
HIV-AIDS [17,18].
We also found elevated TSF values in females com-
pared to males indicating an elevated risk for obesity
and related cardiovascular risk. Moreover, when the total
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lowing 12 months of HAART [19]. Likewise George
et al. [19] reported decreased TSF values in a black
South African HIV-positive population (18–55 years,
65% female) until 27 months after anti-retroviral treat-
ment initiation [20]. For the current study, females
also exhibited a significant degree of muscle wasting at
the <3 years HAART time point. A similar biphasic
pattern was observed for BCM, FFM, and FM. Why
the initial reduction in such parameters following
HAART? Some suggested that endocrine, environmen-
tal and socio-economic factors may be potential expla-
nations [21]. However, we propose that the decrease in
the anthropometric and BIA characteristics within the
first three years of treatment can most likely be attrib-
uted to the stabilization of the immune system and
metabolism that occur as a result of the infection and
the introduction of HAART. Moreover, oxidation of
visceral fat for energy utilization could be an add-
itional factor to help explain the reduction in waist
and hip circumferences (<3 years HAART). Further-
more, with any chronic disease (especially HIV
infection) the resting energy expenditure (REE) is
enhanced [22]. Such findings are of clinical signifi-
cance since an elevated REE may also impair muscle
mass gain [23]. However, further studies are required
to ascertain whether these proposals are valid and to
also evaluate nutritional status/food security in this
particular population.Literature suggests that both TSF and mid-upper arm
circumference (MUAC) are independent predictors for
survival, and surrogate parameters for muscle wasting
[24,25]. Both parameters can also be employed to deter-
mine the risk for possible co-infections [25]. For males
we observed no differences for TSF or MUAC as treat-
ment duration increased. Moreover, the initial attenu-
ation in TSF and MUAC (<3 years HAART) for females
returned to baseline levels suggesting that long-term
HAART may lower the risk for co-infections and thus
increase survival rates.
Muscle mass, FFM and FM did not significantly differ
in males for the different HAART groups compared to
the HAART-naïve one. Although there is a tendency for
weight loss amongst males in the <3 year HAART com-
pared to the HAART-naïve group (p = 0.08) (data not
shown), the variability in weight in the >3 year HAART
group makes comparisons non-significant. However,
inclusion of more subjects (particularly males) may shed
greater light on this question.
Waist-to-hip ratios were also assessed as a marker for
cardio-metabolic risk [26,27]. Females in the HAART-
naïve and treatment groups presented with a higher risk
for cardio-metabolic complications since W:H ratios
were above standard cut-off levels [28,29]. However,
males were not at risk since the W:H ratios were lower
than standard cut-off criteria [29]. Since females appear
to be at greater risk, we also determined the potential
relationship between central obesity and CD4 T-cell
Nell et al. BMC Infectious Diseases  (2015) 15:85 Page 9 of 10counts. The proposed association between central obes-
ity (W:H ratio) and CD4 can be explained by leptin
(secreted by adipocytes) aiding in the proliferation of
CD4+ T-cells [30]. Here the weak correlation for fe-
males in the <3 year HAART group was expected since
most of the parameters investigated were decreased at
this time point. However, with prolonged HAART
females displayed a higher risk for future cardio-
metabolic dysfunction.
We acknowledge that the present study has some limi-
tations, one being the intrinsic limitation of a cross-
sectional design. Although our findings demonstrated
clear gender-based differences, another limitation is the
relatively low number of male participants (compared to
females). This observation is in accordance with previ-
ous work where males were also less likely to attend
clinics and participate in research studies [31]. This is
mainly due to males being the sole breadwinner and
thus unable to take time off from work to receive med-
ical care and/or participate in research projects.
Although nutritional status would have provided valu-
able insight into caloric intake and further strengthened
our results, this could not be performed due to logis-
tical reasons and lengthy patient contact time required.
Finally, this study lacked an HIV-negative control
group to compare an HIV-infected population with a
non-infected one.
Conclusions
The current study established unique gender-based dif-
ferences in a peri-urban black South African HIV-
infected population. Unlike males, females displayed
initial muscle wasting but thereafter gained weight (sig-
nificantly higher W:H ratios) with prolonged treatment.
Thus these data suggest that female HIV-positive indi-
viduals on longer-term HAART may be at greater risk
for the development of cardio-metabolic disease compli-
cations. Future studies should focus on determining the
cause of the body compositional changes undergone
with treatment duration and distinguish between the
influence of HIV itself and the treatment thereof. The
multiple anthropometric and body compositional charac-
teristics described provided robust insights into changes
observed with increasing HAART duration. This rein-
forces the importance of basic anthropometric measure-
ments that are fairly quick, cost-effective and easy to
perform in peri-urban and rural settings to aid in identify-
ing patients at risk for HAART-related co-morbidities.
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